AEON AEON Biopharma, Inc.

NYSE aeonbiopharma.com


$ 0.92 $ -0.11 (-10.9 %)    

Thursday, 23-Oct-2025 15:43:48 EDT
QQQ $ 611.70 $ 5.09 (0.84 %)
DIA $ 467.20 $ 1.51 (0.32 %)
SPY $ 672.21 $ 3.96 (0.59 %)
TLT $ 91.38 $ -0.63 (-0.68 %)
GLD $ 378.90 $ 1.51 (0.4 %)
$ 0.9088
$ 1.02
$ 0.88 x 500
$ 1.11 x 250
-- - --
$ 0.38 - $ 74.16
448,920
na
1.06M
$ 0.57
$ 0.03
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 07-21-2023 06-30-2023 10-Q
10 05-17-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 06-15-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aegis-capital-reiterates-buy-on-aeon-biopharma-maintains-72-price-target

Aegis Capital analyst David Bouchey reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $7.2 price target.

 fda-schedules-biosimilar-biological-product-development-type-2a-meeting-with-aeon-biopharma-regarding-abp-450

- Meeting date aligns with prior guidance -- FDA to review AEON's analytical development plan and initial data -

 aeon-biopharma-q2-eps-060-beats-1152-estimate

AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(11.52)...

 aeon-biopharma-announces-1-for-72-reverse-stock-split

AEON Biopharma, Inc. (NYSE:AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a bo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION